ACUTE MYELOID LEUKEMIA IN CHILDREN AND ADOLESCENTS IN BRAZILIAN INSTITUTIONS: REALITY AND CHALLENGES
DOI:
https://doi.org/10.46765/2675-374X.2020v2n1p77-86Keywords:
Pediatric AML. HSCT. BrazilAbstract
Objective: To describe the outcome of acute myeloid leukemia (AML) among children treated in Brazilian institutions. Methods: A structured online questionnaire was sent to pediatric oncologists affiliated to the Brazilian Society of Pediatric Oncology. The physicians and institutions were unidentified. Results: One hundred and four pediatric oncologists in all Brazilian regions answered the questionnaire. The treatment-related mortality rate was reported to be higher than 30% by 29.8% of the participants. Difficulty in accessing the intensive care unit (ICU) was reported by 54.8%. About 85% had access to cytogenetics, 78% to molecular testing, 94% to the measurement of residual disease by flow cytometry. About 90% of participants reported access to HSCT, but 86% of them had difficulties in providing HSCT timely. About 95% of the respondents indicated the need to create a national treatment protocol, and 89.4% are willing to collaborate with a national study group. Conclusion: Our study demonstrated large gaps in the treatment of pediatric AML in Brazil. To improve outcome, a national protocol will have to consider the regional differences and adapt the management according to the local resources.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Ana Luiza de Melo Rodrigues, Luana Lenzi, Lisa Lee-Jones, Alayde Vieira Wanderley, Ana Maria Marinho Da Silva, Cinthya Rocha De Carvalho, Juliana Teixeira Costa, Cláudio Galvão De Castro Junior, Maria Lucia De Martino Lee, Mecneide Mendes Lins, Patrick Rezende Godinho, Raul Correa Ribeiro

This work is licensed under a Creative Commons Attribution 4.0 International License.
